Levemir® is available on 94% of Commercial and Medicare Part D plans.1,a

Check formulary coverage for your patients.
 

Levemir® offers comparable formulary coverage to insulin glargine U-100

Formulary status of Levemir® FlexTouch® vs insulin glargine U-100 SoloSTAR®1,a

 

Levemir® FlexTouch® vs. insulin glargine U-100 SoloSTAR®

aFormulary Data Source: Fingertip Formulary; March 2016. Due to rounding, numbers may not add up to 100%.
bIncludes Health Maintenance Organization (HMO), Preferred Provider Organization (PPO), and Point of Service (POS) plans. Does not include Medicaid or Medicare Part D.
cIncludes Medicare Advantage Prescription Drug (MAPD) plans and Part D plans (PDP).

Formulary status is subject to change.

Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs. This information should not be used to make efficacy or safety comparisons between or among mentioned products. Multiple products in the same therapeutic class may be considered “preferred” and on the same tier. Medicare Part D data is on file with Novo Nordisk and current as of March 2016.

 


Check formulary coverage in your area

Loading...

 

 

One box of Levemir® FlexTouch® provides 50% more insulin than a vial for the same co-pay on most managed care plans

  • One prescription for FlexTouch® (1 box of 5 pens) = 1500 units
  • One prescription for vial = 1000 units 

 

 

Needles and FlexTouch® are for single patient use only. Patients should never share a Levemir® FlexTouch® between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
Needles are sold separately and may require a prescription in some states.

 

 

Units of Levemir® vial and FlexTouch® per box

Co-pay Calculator
This online tool helps your patients calculate their exact Levemir® co-pay in a few short steps before they go to the pharmacy.


Access the Patient Assistance Program
The Novo Nordisk Patient Assistance Program (PAP) can help your patients who have difficulty affording their medications. 

Related Prescribing Topics:


 

Selected Important Safety Information

Contraindications

  • Levemir® is contraindicated in patients with hypersensitivity to Levemir® or any of its excipients.

Warnings and Precautions

  • Never Share a Levemir® FlexTouch® Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
  • Dosage adjustment and monitoring: Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment of concomitant anti-diabetic treatment.
  • Administration: Do not dilute or mix with any other insulin or solution. Do not administer subcutaneously via an insulin pump, intramuscularly, or intravenously because severe hypoglycemia can occur. 

Levemir® (insulin detemir [rDNA origin] injection) Indications and Usage

  • Levemir® (insulin detemir [rDNA origin] injection) is indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Limitations of Use

  • Levemir® is not recommended for the treatment of diabetic ketoacidosis. Intravenous rapid-acting or short-acting insulin is the preferred treatment for this condition.

Important Safety Information

Contraindications

  • Levemir® is contraindicated in patients with hypersensitivity to Levemir® or any of its excipients.

Warnings and Precautions

  • Never Share a Levemir® FlexTouch® Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
  • Dosage adjustment and monitoring: Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in the insulin dose or an adjustment of concomitant anti-diabetic treatment.
  • Administration: Do not dilute or mix with any other insulin or solution. Do not administer subcutaneously via an insulin pump, intramuscularly, or intravenously because severe hypoglycemia can occur.

  • Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin therapy and may be life-threatening. When a GLP-1 receptor agonist is used in combination with Levemir®, the Levemir® dose may need to be lowered or more conservatively titrated to minimize the risk of hypoglycemia.

  • Hypersensitivity and allergic reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Levemir®.

  • Renal and hepatic impairment: Careful glucose monitoring and dose adjustments of insulin, including Levemir®, may be necessary in patients with renal or hepatic impairment.
  • Drug interactions: Some medications may alter insulin requirements and subsequently increase the risk for hypoglycemia or hyperglycemia.
  • Fluid retention and heart failure with concomitant use of PPAR-gamma agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Levemir®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered.

Adverse Reactions

  • Adverse reactions associated with Levemir® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, rash, pruritus, and if taken with a GLP-1 receptor agonist, diarrhea.

Use in Specific Populations

  • Levemir® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age.

  • The background risk of birth defects, pregnancy loss, or other adverse events that exists for all pregnancies is increased in pregnancies complicated by hyperglycemia.

Please click here for Prescribing Information.

 

Reference

  1. Fingertip Formulary; March 2016.